PA8457901A1 - Terapia de combinacion - Google Patents

Terapia de combinacion

Info

Publication number
PA8457901A1
PA8457901A1 PA19988457901A PA8457901A PA8457901A1 PA 8457901 A1 PA8457901 A1 PA 8457901A1 PA 19988457901 A PA19988457901 A PA 19988457901A PA 8457901 A PA8457901 A PA 8457901A PA 8457901 A1 PA8457901 A1 PA 8457901A1
Authority
PA
Panama
Prior art keywords
combinations
atorvastatina
subsidiaries
symptoms
pharmaceutically acceptable
Prior art date
Application number
PA19988457901A
Other languages
English (en)
Inventor
Robert Andrew Donald Scott
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8457901A1 publication Critical patent/PA8457901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

ESTA INVENCION SE REFIERE A COMBINACIONES FARMACEUTICAS DE ATORVASTATINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y AGENTES ANTIHIPERTENSORES, ESTUCHES DE ENSAYO QUE CONTIENEN DICHAS COMBINACIONES Y PROCEDIMIENTOS PARA UTILIZAR DICHAS COMBINACIONES PARA TRATAR SUJETOS QUE SUFREN ANGINA PECTORIS, ATEROESCLEROSIS, HIPERTENSION E HIPERLIPIDEMIA COMBINADAS Y PARA TRATAR SUJETOS QUE PRESENTEN SINTOMAS DE RIESGO CARDIACO, INCLUYENDO SERES HUMANOS. ESTA INVENCION SE REFIERE TAMBIEN A COMBINACIONES ADITIVAS Y SINERGICAS DE ATORVASTATINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y AGENTES ANTIHIPERTENSORES POR LOS QUE ESTAS COMBINACIONES SINERGICAS SON UTILES EN EL TRATAMIENTO DE SUJETOS QUE SUFREN DE ANGINA PECTORIS, ATEROESCLEROSIS, HIPERTENSION E HIPERLIPIDEMIA COMBINADAS Y AQUELLOS SUJETOS QUE PRESENTEN SINTOMAS DE RIESGO CARDIACO, INCLUYENDO LOS SERES HUMANOS.
PA19988457901A 1997-08-29 1998-08-17 Terapia de combinacion PA8457901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5727697P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
PA8457901A1 true PA8457901A1 (es) 2000-05-24

Family

ID=22009602

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19988457901A PA8457901A1 (es) 1997-08-29 1998-08-17 Terapia de combinacion

Country Status (41)

Country Link
US (2) US20020099046A1 (es)
EP (1) EP1009400B1 (es)
JP (2) JP2001514223A (es)
KR (3) KR20030015394A (es)
CN (3) CN1473567A (es)
AP (1) AP1191A (es)
AR (1) AR016399A1 (es)
AT (1) ATE285767T1 (es)
AU (1) AU740424B2 (es)
BG (1) BG64724B1 (es)
BR (1) BR9811556A (es)
CA (1) CA2296723A1 (es)
CO (1) CO4970724A1 (es)
DE (1) DE69828413T2 (es)
DZ (1) DZ2595A1 (es)
EA (1) EA200000012A1 (es)
EG (1) EG24678A (es)
ES (1) ES2234134T3 (es)
GT (1) GT199800126A (es)
HR (1) HRP980474A2 (es)
HU (1) HUP0004318A3 (es)
ID (1) ID24118A (es)
IL (2) IL133962A0 (es)
IS (1) IS5341A (es)
MA (1) MA26536A1 (es)
MY (1) MY121008A (es)
NO (1) NO323987B1 (es)
NZ (2) NZ530630A (es)
OA (1) OA11291A (es)
PA (1) PA8457901A1 (es)
PE (1) PE107099A1 (es)
PL (1) PL339091A1 (es)
PT (1) PT1009400E (es)
SA (1) SA98190603B1 (es)
SK (1) SK1432000A3 (es)
TN (1) TNSN98155A1 (es)
TR (1) TR200000563T2 (es)
UY (1) UY25155A1 (es)
WO (1) WO1999011260A1 (es)
YU (1) YU2000A (es)
ZA (1) ZA987839B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
CA2309588A1 (en) * 1998-03-17 1999-09-23 Warner-Lambert Company Statin-matrix metalloproteinase inhibitor combinations
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
AU2007200367B2 (en) * 1999-02-06 2010-04-08 Astrazeneca Ab Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE60024114T2 (de) 1999-09-24 2006-08-03 Vasogen Ireland Ltd., Shannon Zusammensetzung zur behandlung von atherosklerose, welche ein statin und ex-vivo behandeltes blut enthält
FR2803525B1 (fr) * 2000-01-06 2002-05-03 Sod Conseils Rech Applic Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
SK287558B6 (sk) 2000-07-19 2011-02-04 Novartis Ag Soli valsartanu, ich použitie, spôsob ich výroby a farmaceutické prípravky obsahujúce tieto soli
AU2001284413A1 (en) * 2000-08-30 2002-03-13 Sankyo Company Limited Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) * 2000-10-23 2006-03-28 Euro-Celtique, S.A. Felodipine transdermal device and methods
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
OA12983A (en) * 2001-07-19 2006-10-13 Pharmacia Corp Combination of an aldosterone receptor antagonist and an HMG COA reductase inhibitor.
PE20030324A1 (es) * 2001-07-31 2003-04-03 Warner Lambert Co Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ATE395936T1 (de) * 2002-06-20 2008-06-15 Univ Alberta Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
BR0312102A (pt) * 2002-06-27 2007-05-29 Sb Pharmco Inc sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
GB0221579D0 (en) * 2002-09-17 2002-10-23 Pfizer Ltd Combinations of atorvastatin and, adrenergic receptor antagonists
AU2003274004A1 (en) * 2002-10-16 2004-05-04 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7750036B2 (en) * 2003-11-25 2010-07-06 Sb Pharmco Puerto Rico Inc. Carvedilol salts, corresponding compositions, methods of delivery and/or treatment
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
KR20050092519A (ko) * 2004-03-16 2005-09-22 화이자 인코포레이티드 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
WO2005099700A1 (en) * 2004-04-06 2005-10-27 Merck & Co., Inc. Methods for the treatment of hypertension
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CA2578224A1 (en) 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
KR20070111468A (ko) * 2005-02-17 2007-11-21 키에시 파르마슈티시 엣스. 피. 에이. 마니디핀과 스타틴의 치료용 복합물
WO2007111027A1 (ja) 2006-03-29 2007-10-04 Kowa Co., Ltd. トリグリセリド低下剤及び高インスリン血症改善剤
US8642083B2 (en) * 2006-10-30 2014-02-04 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
CZ2008740A3 (cs) * 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
UA102721C2 (uk) * 2009-01-23 2013-08-12 Ханми Сайенс Ко., Лтд. Тверда фармацевтична композиція, яка містить амлодипін і лозартан, і спосіб її отримання
SI23149A (sl) * 2009-09-21 2011-03-31 Silverstone Pharma Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) * 2011-10-27 2013-05-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) * 2011-12-17 2012-09-19 东莞达信生物技术有限公司 一种降压降脂复方药及其制备方法
KR20140028971A (ko) * 2012-08-31 2014-03-10 한미약품 주식회사 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
AU2014230304B2 (en) * 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
CN104173420A (zh) * 2013-05-20 2014-12-03 广州诺氏刘生物科技有限公司 一种治疗急性肾衰竭的药物
AU2015335841B2 (en) 2014-10-23 2020-06-25 Arena Pharmaceuticals, Inc. Method of treating conditions related to the PGI2 receptor
MX2017014311A (es) * 2015-06-30 2018-03-07 Hanmi Pharm Ind Co Ltd Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
FR3040303B1 (fr) * 2015-08-27 2019-04-05 Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) * 2015-11-19 2016-01-13 哈尔滨圣吉药业股份有限公司 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
WO2017210467A1 (en) * 2016-06-02 2017-12-07 Ana Pharmaceuticals, Inc. Methods and compositions for treatment of hypercalciuria and nephrolithiasis
CA3051374A1 (en) 2017-01-25 2018-08-02 The George Institute for Global Health Compositions for the treatment of hypertension
ES2897024T3 (es) 2017-03-01 2022-02-28 Arena Pharm Inc Composiciones que comprenden agonistas del receptor de PGI2 y procesos para la preparación de las mismas
CA3107616A1 (en) * 2018-07-26 2020-01-30 The George Institute for Global Health Compositions for the treatment of hypertension
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) * 1994-08-24 1995-09-05 Bristol-Myers Squibb Company α-phosphonosulfinic squalene synthetase inhibitors
US5798375A (en) * 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
AU720853B2 (en) * 1995-11-02 2000-06-15 Warner-Lambert Company Method and pharmaceutical composition for regulating lipid concentration

Also Published As

Publication number Publication date
IS5341A (is) 2000-01-14
ZA987839B (en) 2000-02-28
EP1009400B1 (en) 2004-12-29
NO20000996D0 (no) 2000-02-28
CO4970724A1 (es) 2000-11-07
PE107099A1 (es) 1999-11-06
ATE285767T1 (de) 2005-01-15
NO20000996L (no) 2000-04-27
HUP0004318A3 (en) 2002-10-28
BR9811556A (pt) 2000-08-22
JP2005041875A (ja) 2005-02-17
AP9801332A0 (en) 1998-09-30
MA26536A1 (fr) 2004-12-20
NO323987B1 (no) 2007-07-30
EG24678A (en) 2010-04-27
UY25155A1 (es) 2000-12-29
ID24118A (id) 2000-07-06
EA200000012A1 (ru) 2000-08-28
SK1432000A3 (en) 2000-12-11
TR200000563T2 (tr) 2000-07-21
NZ502280A (en) 2002-11-26
PL339091A1 (en) 2000-12-04
KR20010022477A (ko) 2001-03-15
US20020099046A1 (en) 2002-07-25
IL133962A (en) 2006-07-05
HRP980474A2 (en) 1999-06-30
CN1473566A (zh) 2004-02-11
EP1009400A1 (en) 2000-06-21
AU8458998A (en) 1999-03-22
BG64724B1 (bg) 2006-01-31
AR016399A1 (es) 2001-07-04
AP1191A (en) 2003-07-19
HUP0004318A2 (hu) 2001-05-28
CA2296723A1 (en) 1999-03-11
YU2000A (sh) 2002-12-10
CN1473567A (zh) 2004-02-11
AU740424B2 (en) 2001-11-01
TNSN98155A1 (fr) 2005-03-15
OA11291A (en) 2003-08-25
KR20040106591A (ko) 2004-12-17
PT1009400E (pt) 2005-02-28
KR20030015394A (ko) 2003-02-20
ES2234134T3 (es) 2005-06-16
JP2001514223A (ja) 2001-09-11
DE69828413T2 (de) 2005-12-08
CN1268053A (zh) 2000-09-27
SA98190603B1 (ar) 2006-07-04
WO1999011260A1 (en) 1999-03-11
US20030199492A1 (en) 2003-10-23
NZ530630A (en) 2005-05-27
DZ2595A1 (fr) 2003-02-22
GT199800126A (es) 2000-01-29
DE69828413D1 (de) 2005-02-03
MY121008A (en) 2005-12-30
IL133962A0 (en) 2001-04-30
BG104075A (en) 2000-09-29

Similar Documents

Publication Publication Date Title
PA8457901A1 (es) Terapia de combinacion
PA8457101A1 (es) Combinaciones terapeuticas
GT199800134A (es) Terapia de combinacion.
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
CY1106974T1 (el) Πολυδυναμη θεραπεια για επιτελεση απωλειας βαρους και θεραπευτικη αντιμετωπιση της παχυσαρκιας
UY26163A1 (es) Sal mutua de amlodipino y atorvastatina
PA8462401A1 (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
ES2133270T3 (es) Terapia de combinacion para la profilaxis y/o el tratamiento de hiperplasia prostatica benigna.
ES2058185T3 (es) Derivados de camptotecina y procedimiento para su preparacion.
GT199700079A (es) Derivados triciclos sustituidos con fenilamino
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
AR003119A1 (es) Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
PA8457001A1 (es) Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol
HN2000000075A (es) Profarmacos mutuos amlodipino y atorvastatina
BR9608255A (pt) Sistema terapéutico transdérmico (stt) para a administração de testosterona
DE69933671D1 (de) Adenosin a1 antagonisten gegen männliche sterilität
ES2186153T3 (es) Sulfato de 5-alfa-pregnan-3-beta-ol-20-ona para el tratamiento de tumores y de los trastornos del snc.
ECSP982647A (es) Terapia de combinacion
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.
ECSP982646A (es) Combinaciones terapeuticas
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.
UY27510A1 (es) Terapia de combinación